In addition, none of the previous studies [19], [20], [21], [22], [23], [24], [25] has comprehensively examined potential confounding effect of key molecular biomarkers in colorectal cancer, including the CpG island methylator phenotype (CIMP), and KRAS, BRAF and PIK3CA mutations. This evidence concerns the gene KRAS and colorectal cancer.